207 related articles for article (PubMed ID: 22484426)
1. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.
Leskov I; Pallasch CP; Drake A; Iliopoulou BP; Souza A; Shen CH; Schweighofer CD; Abruzzo L; Frenzel LP; Wendtner CM; Hemann MT; Chen J
Oncogene; 2013 Feb; 32(8):1066-1072. PubMed ID: 22484426
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.
Nakagawa M; Tsuzuki S; Honma K; Taguchi O; Seto M
Haematologica; 2011 Sep; 96(9):1318-26. PubMed ID: 21606168
[TBL] [Abstract][Full Text] [Related]
3. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
4. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
6. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
[TBL] [Abstract][Full Text] [Related]
7. "Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.
Eldessouki T; Hanley K; Hamadeh F; Oshilaja OO; Sturgis CD
Diagn Cytopathol; 2018 Sep; 46(9):807-811. PubMed ID: 30043475
[TBL] [Abstract][Full Text] [Related]
8. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
9. Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.
Dheur MS; Poirel HA; Ameye G; Tilman G; Saussoy P; Defour JP; Camboni A; Van Den Neste E; Coulie PG; van Baren N
Leuk Lymphoma; 2019 Apr; 60(4):1043-1052. PubMed ID: 30277098
[TBL] [Abstract][Full Text] [Related]
10. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
[TBL] [Abstract][Full Text] [Related]
11. A clinician's guide to double hit lymphomas.
Cheah CY; Oki Y; Westin JR; Turturro F
Br J Haematol; 2015 Mar; 168(6):784-95. PubMed ID: 25529575
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
[TBL] [Abstract][Full Text] [Related]
13. Double hit and double expressors in lymphoma: Definition and treatment.
Riedell PA; Smith SM
Cancer; 2018 Dec; 124(24):4622-4632. PubMed ID: 30252929
[TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC.
Pham LV; Lu G; Tamayo AT; Chen J; Challagundla P; Jorgensen JL; Medeiros LJ; Ford RJ
J Hematol Oncol; 2015 Oct; 8():121. PubMed ID: 26515759
[TBL] [Abstract][Full Text] [Related]
15. Management of Patients with MYC-Altered Lymphomas.
Landsburg DJ
Curr Hematol Malig Rep; 2016 Jun; 11(3):208-17. PubMed ID: 26983958
[TBL] [Abstract][Full Text] [Related]
16. Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
Drexler HG; Eberth S; Nagel S; MacLeod RA
Leuk Lymphoma; 2016 May; 57(5):1015-20. PubMed ID: 26727417
[TBL] [Abstract][Full Text] [Related]
17. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.
Miura K; Takahashi H; Nakagawa M; Izu A; Sugitani M; Kurita D; Sakagami M; Ohtake S; Uchino Y; Hojo A; Kodaira H; Yagi M; Kobayashi Y; Iriyama N; Kobayashi S; Kiso S; Hirabayashi Y; Hatta Y; Takei M
Leuk Lymphoma; 2016; 57(6):1335-41. PubMed ID: 26390147
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.
Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K
Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092
[TBL] [Abstract][Full Text] [Related]
20. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND
Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]